9月30日 - ** 制药公司Celcuity（CELC.O）的股价在盘前交易中上涨4.11%，至80.56美元
** 该公司表示，其获美国食品药品监督管理局（FDA）批准的乳腺癌药物Revtorpyk现已在美国上市
** 该药物 (link) 获批与氟维斯坦（fulvestrant）联合使用，可搭配或不搭配辉瑞公司 PFE.N 的Ibrance，适用于部分晚期乳腺癌患者——其肿瘤未携带PIK3CA基因突变，且在激素治疗后病情恶化
** Citizens估计，该药一个月的用量费用为30,000美元，并预测Revtorpyk在2026年的销售额将达到650万美元
** 该券商维持“跑赢大盘”评级和177美元的目标价，理由是该药物的疗效以及Celcuity为上市所做的准备
** CELC 还正在申请 FDA 批准 Revtorpyk 用于肿瘤存在 PIK3CA 突变的患者，这可能扩大该药物的适用范围
** 截至上一交易日收盘，CELC今年以来累计下跌22.4%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.